Phenacetin O-deethylase activity of the rat: strain differences and the effects of enzyme-inducing compounds

References

• Al-Dabbagh S. G., Idle J. R., Smith R. L. Animal modelling of human polymorphic drug oxidation—the metabolism of debrisoquine and phenacetin in rat inbred strains. Journal of Pharmacy and Pharmacology 1981; 33: 161–164
   PubMed Web of Science ®Google Scholar
• Atlas S. A., Boobis A. R., Felton J. S., Thorgeirsson S. S., Nebert D. W. Ontogenetic expression of polycyclic aromatic compound-inducible monooxygenase activities and forms of cytochrome P-450 in rabbit. Journal of Biological Chemistry 1977; 252: 4712–4721
   PubMed Web of Science ®Google Scholar
• Boobis A. R., Nebert D. W., Felton J. S. Comparison of β-naphthoflavone and 3-methylcholanthrene as inducers of hepatic cytochrome(s) P.448 and aryl hydrocarbon (benzo[a]pyrene) hydroxylase activity. Molecular Pharmacology 1977; 13: 259–268
   PubMed Web of Science ®Google Scholar
• Boobis A. R., Brodie M. J., Kahn G. C., Fletcher D. R., Saunders J. H., Davies D. S. Monooxygenase activity of human liver microsomal fractions of needle biopsy specimens. British Journal of Clinical Pharmacology 1980; 9: 11–19
   PubMed Web of Science ®Google Scholar
• Boobis A. R., Kahn G. C., Whyte C., Brodie M. J., Davies D. S. Biphasic O-deethylation of phenacetin and 7-ethoxycoumarin by human and rat liver microsomal fractions. Biochemical Pharmacology 1981; 30: 2451–2456
   PubMed Web of Science ®Google Scholar
• Conney A. H., Sansur M., Soroko F., Koster R., Burns J. J. Enzyme induction and inhibition in the studies on the pharmacological actions of acetophenetidin. Journal of Pharmacology and Experimental Therapeutics 1966; 151: 133–138
   PubMed Web of Science ®Google Scholar
• Davies D. S., Kahn G. C., Murray S., Brodie M. J., Boobis A. R. Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver. British Journal of Clinical Pharmacology 1981; 11: 89–91
   PubMed Web of Science ®Google Scholar
• Distlerath L. M., Guengerich F. P. Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme. Proceedings of the National Academy of Sciences, USA 1984; 81: 7348–7352
   PubMed Web of Science ®Google Scholar
• Distlerath L. M., Reilly P. E. B., Martin M. V., Davis G. C., Wilkinson G. R., Guengerich F. P. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry 1985; 260: 9057–9067
   PubMed Web of Science ®Google Scholar
• Idle J. R., Smith R. L. The debrisoquine hydroxylation gene: a gene of multiple consequences. Proceedings of the Second World Conference on Clinical Pharmacology and Therapeutics. 1984, L. Lemberger, M. M. Reidenberg. American Society for Experimental Pharmacology and Therapeutics, Bethesda, MD, 148–164
   Google Scholar
• Inaba T., Otton S. V., Kalow W. Debrisoquine hydroxylation capacity: problems of assessment of two populations. Clinical Pharmacology and Therapeutics 1981; 29: 218–223
   PubMedGoogle Scholar
• Kahn G. C., Boobis A. R., Brodie M. J., Toverud E. -L., Murray S., Davies D. S. Phenacetin O-deethylase: an activity of a cytochrome P-450 showing genetic linkage with that catalysing the 4-hydroxylation of debrisoquine. British Journal of Clinical Pharmacology 1985a; 20: 67–76
   PubMed Web of Science ®Google Scholar
• Kahn G. C., Rubenfield M., Davies D. S., Murray S., Boobis A. R. Sex and strain differences in hepatic debrisoquine 4-hydroxylase activity of the rat. Drug Metabolism and Disposition 1985b; 13: 510–516
   PubMedGoogle Scholar
• Kleinbloesem C. H., Van Brummelen P., Faber H., Danhof M., Vermeulen N. P. E., Breimer D. D. Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochemical Pharmacology 1984; 33: 3721–3724
   PubMed Web of Science ®Google Scholar
• Koeppe P., Hamann C. A program for non-linear regression analysis to be used on desk-top computers. Computer Programs in Biomedicine 1980; 12: 121–128
   PubMedGoogle Scholar
• Kupfer A., Desmond P., Patwardhan R., Schenker S., Branch R. Mephenytoin hydroxylation deficiency: kinetics after repeated doses. Clinical Pharmacology and Therapeutics 1984; 35: 33–39
   PubMed Web of Science ®Google Scholar
• Larrey D., Distlerath L. M., Dannan G. A., Wilkinson G. R., Guengerich F. P. Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism. Biochemistry 1984; 23: 2787–2795
   PubMed Web of Science ®Google Scholar
• Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of debrisoquine in man. The Lancet 1977; ii: 584–586
   Web of Science ®Google Scholar
• Mahgoub A., Idle J. R., Smith R. L. A population and familial study of the defective alicyclic hydroxylation of debrisoquine among Egyptians. Xenobiotica 1979; 9: 51–56
   PubMed Web of Science ®Google Scholar
• Poppers P. J., Levin W., Conney A. H. Effect of 3-methylcholanthrene treatment on phenacetin O-deethylation in several inbred mouse strains. Drug Metabolism and Disposition 1975; 3: 502–506
   PubMedGoogle Scholar
• Price Evans D. A., Mahgoub A., Sloan T. P., Idle J. R., Smith R. L. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. Journal of Medical Genetics 1980; 17: 102–105
   PubMed Web of Science ®Google Scholar
• Scott J., Poffenbarger P. L. Pharmacogenetics of tolbutamide metabolism in humans. Diabetes 1979; 28: 41–51
   PubMed Web of Science ®Google Scholar
• Shahidi N. T. Acetophenetidin-induced methemoglobinemia. Annals of the New York Academy of Sciences 1968; 151: 822–832
   PubMed Web of Science ®Google Scholar
• Sloan T. P., Mahgoub A., Lancaster R., Idle J. R., Smith R. L. Polymorphism of carbon oxidation of drugs and clinical implications. British Medical Journal 1978; 2: 655–657
   PubMed Web of Science ®Google Scholar
• Waring R. H., Mitchell S. C., Idle J. R., Smith R. L. Genetically determined impaired drug oxidation. The Lancet 1981; i: 778
   Google Scholar
• Welch R. M., Hughes C. R., Deangelis R. L. Effect of 3-methylcholanthrene pretreatment on the bioavailability of phenacetin in the rat. Drug Metabolism and Disposition 1976; 4: 402–06
   PubMed Web of Science ®Google Scholar